Abstract
Inflammation plays a significant role in atherosclerosis and cardiovascular disease (CVD). Patients with chronic inflammatory diseases are at increased risk of CVD, but it is debated whether this association is causal or dependent on shared risk factors, other exposures, genes, and/or inflammatory pathways. The current review summarizes epidemiological, clinical, and experimental data supporting the role of shared inflammatory mechanisms between atherosclerotic CVD and rheumatoid arthritis, psoriasis, inflammatory bowel disease, and periodontitis, respectively, and provides insights to future prospects in this area of research. Awareness of the role of inflammation in CVD in patients with chronic inflammatory diseases and the potential for anti-inflammatory therapy, e.g., with tumor necrosis factor-α inhibitors, to also reduce atherosclerotic CVD has evolved into guideline- based recommendations. These include regular CVD risk assessment, aggressive treatment of traditional CVD risk factors, and recognition of reduced CVD as an added benefit of strict inflammatory disease control. At present, chronic inflammatory diseases would appear to qualify as partners in crime and not merely innocent bystanders to CVD. However, definite incremental contributions of inflammation versus effects of the complex interplay with other CVD risk factors may never be fully elucidated and for the foreseeable future, inflammation is posed to maintain its current position as both a marker and a maker of CVD, with clinical utility both for identification of patient at risk of CVD and as target for therapy to reduce CVD.
Keywords: Chronic inflammatory disease, atherosclerosis, cardiovascular disease, inflammation, rheumatoid arthritis, psoriasis, inflammatory bowel disease, periodontitis.
Current Pharmaceutical Design
Title:Chronic Inflammatory Diseases and Atherosclerotic Cardiovascular Disease: Innocent Bystanders or Partners in Crime?
Volume: 24 Issue: 3
Author(s): Peter Riis Hansen *
Affiliation:
- Department of Cardiology, Herlev and Gentofte Hospital, Kildegaardsvej 18, DK-2900 Hellerup,Denmark
Keywords: Chronic inflammatory disease, atherosclerosis, cardiovascular disease, inflammation, rheumatoid arthritis, psoriasis, inflammatory bowel disease, periodontitis.
Abstract: Inflammation plays a significant role in atherosclerosis and cardiovascular disease (CVD). Patients with chronic inflammatory diseases are at increased risk of CVD, but it is debated whether this association is causal or dependent on shared risk factors, other exposures, genes, and/or inflammatory pathways. The current review summarizes epidemiological, clinical, and experimental data supporting the role of shared inflammatory mechanisms between atherosclerotic CVD and rheumatoid arthritis, psoriasis, inflammatory bowel disease, and periodontitis, respectively, and provides insights to future prospects in this area of research. Awareness of the role of inflammation in CVD in patients with chronic inflammatory diseases and the potential for anti-inflammatory therapy, e.g., with tumor necrosis factor-α inhibitors, to also reduce atherosclerotic CVD has evolved into guideline- based recommendations. These include regular CVD risk assessment, aggressive treatment of traditional CVD risk factors, and recognition of reduced CVD as an added benefit of strict inflammatory disease control. At present, chronic inflammatory diseases would appear to qualify as partners in crime and not merely innocent bystanders to CVD. However, definite incremental contributions of inflammation versus effects of the complex interplay with other CVD risk factors may never be fully elucidated and for the foreseeable future, inflammation is posed to maintain its current position as both a marker and a maker of CVD, with clinical utility both for identification of patient at risk of CVD and as target for therapy to reduce CVD.
Export Options
About this article
Cite this article as:
Hansen Riis Peter *, Chronic Inflammatory Diseases and Atherosclerotic Cardiovascular Disease: Innocent Bystanders or Partners in Crime?, Current Pharmaceutical Design 2018; 24 (3) . https://dx.doi.org/10.2174/1381612824666180110102341
DOI https://dx.doi.org/10.2174/1381612824666180110102341 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Metallosis After Swanson Spacer as Indication for Volar Synovectomy 12 Years After Implantation
Current Rheumatology Reviews Foreword
Current Topics in Medicinal Chemistry The Therapeutic Potential of PhospholipaseA2 Inhibitors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued) Suppression of Erosive Arthritis by NF-κB Inhibitors
Current Rheumatology Reviews Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Current Topics in Medicinal Chemistry Recent Advances in the Synthesis and Applications of Reduced Amide Pseudopeptides
Current Medicinal Chemistry Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
Current Pharmaceutical Design Introduction from Editor-in-Chief
Current Rheumatology Reviews Interleukin-18, From Neuroinflammation to Alzheimers Disease
Current Pharmaceutical Design Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens
Current Topics in Medicinal Chemistry A Study on the Biological Activity of 2-thioxo-imidazolidin-4-ones
Letters in Drug Design & Discovery Polymeric Micelles for the Delivery of Diclofenac and Its Ethyl Ester Derivative
Pharmaceutical Nanotechnology